Last reviewed · How we verify
Bellozal (BILASTINE)
At a glance
| Generic name | BILASTINE |
|---|---|
| Drug class | bilastine |
| Target | Histamine H1 receptor |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
- Allergic rhinitis
- Urticaria
Common side effects
Key clinical trials
- Efficacy of Bilastine Up-dosing (40 mg ) Versus Combination of Bilastine (20 mg )With Levocitirizine (5 mg) in the Treatment of Chronic Spontaneous Urticaria (NA)
- To Compare and Evaluate the Oral Bioavailability of Bilastine 20 mg Orally Dispersible Tablet With That of Bilaxten (Bilastine) 20 mg Orally Dispersible Tablet in Healthy, Adult, Human Subjects Under Fasting Conditions (PHASE1)
- Bioequivalence Study of Bilastine Tablets in Healthy Chinese Subjects (PHASE1)
- Study to Assess the Safety, Tolerability and Efficacy of Bilastine Ophthalmic Solution 0.6% in Children (PHASE3)
- A Study Evaluating Bilastine Ophthalmic Solution 0.6% in the Conjunctival Allergen Challenge (Ora-CAC®) Model. (PHASE3)
- A Single-Center, Phase 2 Study Evaluating Bilastine Ophthalmic Solution in the CAC® Model (PHASE2)
- Modified Xiao-Feng Powder for Chronic Urticaria (PHASE2)
- Efficacy of Co-administration of Bilastine and Montelukast in Patients With SARC and Asthma (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bellozal CI brief — competitive landscape report
- Bellozal updates RSS · CI watch RSS